Skip to main
FBLG
FBLG logo

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. is poised for a positive financial outlook due to its strategic partnership with Charles River, which enhances its manufacturing capabilities and regulatory compliance ahead of clinical trial launches. The company's recent financing achievement of $5 million from Yorkville Advisors strengthens its financial position, allowing for accelerated development of its diverse therapeutic pipeline and ensuring funding for upcoming clinical trials. Additionally, the successful completion of its first-in-human trial for diabetic foot ulcers and the establishment of a robust cell bank position FibroBiologics to leverage its regenerative therapies, further solidifying its leadership status in the regenerative medicine market.

Bears say

FibroBiologics Inc. is facing challenges due to a competitive landscape in the cell therapy market, particularly in addressing chronic conditions like diabetic foot ulcers, where there are limited long-term treatment options. The company's reliance on clinical-stage developments increases its financial risk, as revenues remain uncertain pending successful trials and commercialization. Additionally, the lack of diversified therapies may hinder its ability to capitalize on multiple revenue streams, posing further financial risks.

Fibrobiologics Inc (FBLG) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.